Real-World Effectiveness of Mepolizumab in Patients with Allergic and Non-Allergic Asthma

Figures & data

Figure 1 Study design.

Table 1 Baseline Demographics and Clinical Characteristics

	Allergic Asthma (n=240)	Non-Allergic Asthma (n=298)	p-value
Age, years, mean (SD)	54.8 (15.7)	59.1 (14.3)	< 0.001
Age group, years, n (%)			< 0.001
6–17	9 (3.8)	3 (1.0)	0.040
18–44	43 (17.9)	45 (15.1)	0.413
45–64	127 (52.9)	126 (42.3)	0.015
≥65	61 (25.4)	124 (41.6)	< 0.001
Female, n (%)	157 (65.4)	173 (58.1)	0.091
Race/ethnicity, n (%)			0.729
White	154 (64.2)	185 (62.1)	0.654
African American/Black	29 (12.1)	29 (9.7)	0.404
Asian	5 (2.1)	10 (3.4)	0.438
Hispanic	18 (7.5)	25 (8.4)	0.751
Unknown	34 (14.2)	49 (16.4)	0.549
CCI score, mean (SD)	1.6 (1.2)	1.7 (1.2)	0.748
CCI score, n (%)			0.940
0	0 (0.0)	0 (0.0)	–
1–2	190 (79.2)	232 (77.8)	0.752
3–4	40 (16.7)	53 (17.8)	0.819
5+	10 (4.2)	13 (4.4)	1.000
Baseline OCS use
Any use, n (%)	217 (90.4)	272 (91.3)	0.764
OCS daily dose (mg/day), mean (SD)	4.9 (4.9)	5.6 (5.2)	0.104
Baseline SABA use
Any use, n (%)	202 (84.2)	262 (87.9)	0.211
Count of SABA canisters, mean (SD)	5.0 (6.2)	5.7 (6.5)	0.207

Notes: p-values that reached statistical significance are indicated in bold.

Abbreviations: CCI, Charlson comorbidity index; OCS, oral corticosteroid; SABA, short-acting ß₂-agonist; SD, standard deviation.

Figure 2 Proportion of patients with select comorbidities at baseline. p-values that reached statistical significance are indicated in bold.

Abbreviations: COPD, chronic obstructive pulmonary disease; EGPA, eosinophilic granulomatosis with polyangiitis.

Figure 3 Rate of asthma exacerbations: (A) Proportion of patients with ≥1 asthma exacerbation during baseline and follow-up; (B) Change in mean count of asthma exacerbations between baseline and follow-up. p-values that reached statistical significance are indicated in bold.

Abbreviations: CI, confidence interval; DiD, difference-in-difference.

Table 2 OCS Daily Dose During Baseline and Follow-Up Among All Patients

	Allergic Asthma (n=240)	Non-Allergic Asthma (n=298)
Proportion of patients with ≥1 OCS claim, n (%)
Baseline period	217 (90.4)	272 (91.3)
Follow-up period	182 (75.8)	225 (75.5)
Baseline to follow-up period difference p value	< 0.001	< 0.001
Difference in difference, RR (p-value)	1.129 (p = 0.694)
OCS daily dose, mean (SD)
Baseline period	4.9 (4.9)	5.6 (5.2)
Follow-up period	3.4 (5.0)	3.1 (4.3)
Baseline to follow-up period difference p-value	< 0.001	< 0.001
Difference in difference, RR (p-value)	1.272 (p = 0.008)

Notes: p-values that reached statistical significance are indicated in bold.

Abbreviations: OCS, oral corticosteroid; RR, rate ratio; SD, standard deviation.

Figure 4 OCS use: (A) Mean count of OCS pharmacy claims; (B) Mean count of OCS bursts; (C) Number of patients with chronic OCS use. p-values that reached statistical significance are indicated in bold. *Pre-index counts (ie from Baseline period) are among all allergic (N=240) and non-allergic (N=298) patients; post-index counts (ie from within the 12-month follow-up period) are among patients with chronic OCS use (≥10 mg/day in the 90 days pre-index); ^†Measured during the 90 days period prior to the index date; ^‡Measured during the 12-month follow-up period among patients with chronic OCS use in the 90 days period prior to the index date.

Abbreviations: CI, confidence interval; DiD, difference-in-difference; OCS, oral corticosteroids.